Bluejay Diagnostics (BJDX) EBITDA (2020 - 2026)

Bluejay Diagnostics has disclosed EBITDA across 7 years of filings, most recently posting -$2.3 million for Q2 2026.

• In Q2 2026, EBITDA fell 18.32% year-over-year to -$2.3 million; the TTM figure through Jun 2026 stood at -$7.4 million (down 9.61% YoY), while the FY2025 annual figure was -$7.0 million, up 3.02% from the prior year.
• EBITDA came in at -$2.3 million for Q2 2026 at Bluejay Diagnostics, down from -$1.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.4 million in Q3 2024 to a low of -$2.9 million in Q2 2023.
• Average EBITDA over 5 years is -$2.1 million, with a median of -$2.0 million recorded in 2022.
• Year-over-year, EBITDA plunged 786.91% in 2022 and surged 41.84% in 2024.
• Over 5 years, EBITDA stood at -$2.5 million in 2022, then gained by 2.73% to -$2.4 million in 2023, then jumped by 37.8% to -$1.5 million in 2024, then increased by 1.54% to -$1.5 million in 2025, then plunged by 60.71% to -$2.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$2.3 million in Q2 2026, -$1.9 million in Q1 2026, and -$1.5 million in Q4 2025.